Biological effects of a proglumide derivative as cholecystokinin antagonist in conscious dogs.
In conscious dogs we studied the effects of a new cholecystokinin (CCK) antagonist (coded CR 1505) on CCK8-stimulated exocrine pancreatic secretion and release of pancreatic polypeptide (PP). Graded doses of CCK8 (25-400 ng kg-1h-1) were infused i.v. Experiments were repeated against a background infusion of CR 1505 at different doses (0.1, 1 and 10 mg kg-1h-1). The lowest dose of CR 1505 had no biological effects. However, at the upper two doses the compound significantly inhibited the CCK8-stimulated PP release. Furthermore, a significant inhibition of exocrine pancreatic protein secretion was observed with 10 mg kg-1h-1 of CR 1505 (P less than 0.05). The results suggest that CR 1505 could be a useful tool in defining the physiological role of CCK in vivo.
Hildebrand
P
P
Department of Research, University Hospital, Basel, Switzerland.
Beglinger
C
C
Köhler
E
E
Setnikar
I
I
Gyr
K
K
D000818:Animals; D002766:Cholecystokinin / Q000037:antagonists & inhibitors*; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D005744:Gastric Acid / Q000378:metabolism; D005973:Glutamine / Q000031:analogs & derivatives*; D007262:Infusions, Intravenous; D010189:Pancreatic Juice / Q000378:metabolism*; D010191:Pancreatic Polypeptide / Q000378:metabolism*; D010418:Pentagastrin / Q000494:pharmacology; D011377:Proglumide / Q000031:analogs & derivatives* / Q000494:pharmacology; D012844:Sincalide / Q000494:pharmacology
D005973:Glutamine; D010191:Pancreatic Polypeptide; C053737:loxiglumide; D002766:Cholecystokinin; D010418:Pentagastrin; D011377:Proglumide; D012844:Sincalide